digoxin and Pterygium

digoxin has been researched along with Pterygium* in 1 studies

Other Studies

1 other study(ies) available for digoxin and Pterygium

ArticleYear
Hypoxia-Inducible Factor-Dependent Expression of Angiopoietin-Like 4 by Conjunctival Epithelial Cells Promotes the Angiogenic Phenotype of Pterygia.
    Investigative ophthalmology & visual science, 2017, 09-01, Volume: 58, Issue:11

    Disappointing results from clinical studies assessing the efficacy of therapies targeting vascular endothelial growth factor (VEGF) for the treatment of pterygia suggest that other angiogenic mediators may also play a role in its development. We therefore explore the relative contribution of VEGF, hypoxia-inducible factor (HIF)-1α (the transcription factor that regulates VEGF expression in ocular neovascular disease), and a second HIF-regulated mediator, angiopoietin-like 4 (ANGPTL4), to the angiogenic phenotype of pterygia.. Expression of HIF-1α, VEGF, and ANGPTL4 were examined in surgically excised pterygia, and in immortalized human (ih) and primary rabbit (pr) conjunctival epithelial cells (CjECs). Endothelial cell (EC) tubule formation assays using media conditioned by ihCjECs in the presence or absence of inducers/inhibitors of HIF-1 or RNA interference (RNAi) targeting VEGF, ANGPTL4, or both were used to assess their relative contribution to the angiogenic potential of these cells.. HIF-1α and VEGF expression were detected in 6/6 surgically excised pterygia and localized to CjECs. Accumulation of HIF-1α in was confirmed in ihCjECs and prCjECs, including stratified prCjECs grown on collagen vitrigel, and resulted in expression of VEGF and the promotion of EC tubule formation; the latter effect was partially blocked using RNAi targeting VEGF mRNA expression. We demonstrate expression of a second HIF-regulated angiogenic mediator, ANGPTL4, in CjECs in culture and in surgically excised pterygia. RNAi targeting ANGPTL4 inhibited EC tubule formation and was additive to RNAi targeting VEGF.. Our results support the development of therapies targeting both ANGPTL4 and VEGF for the treatment of patients with pterygia.

    Topics: Angiogenesis Modulating Agents; Angiopoietin-Like Protein 4; Angiopoietins; Animals; Blotting, Western; Cells, Cultured; Conjunctiva; Digoxin; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Epithelial Cells; Gene Expression Regulation; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Neovascularization, Pathologic; Phenotype; Pterygium; Rabbits; Real-Time Polymerase Chain Reaction; RNA Interference; RNA, Messenger; Transfection; Vascular Endothelial Growth Factor A

2017